L'intérêt à découvert pour CERo Therapeutics Hldgs donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de CERo Therapeutics Hldgs. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock, Rapport sur les intérêts à découvert

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

In Reddit's r/povertyfinance, where people swap advice on $5 Walmart meals and how to stretch a tank of gas, <a href="https://www.reddit.com/r/povertyfinance/s/sqNFYmbWzT">one brutally honest confession</a> struck a nerve—and then some.
Another user shared the screenshot with the caption, "How many of us would say this is our future?"
The post read:
"Confession time: I'm almost 49 and I have zero retirement savings. No exaggeration. Absolutely nothing. Maybe about $900 in my checking account. No idea WTF I'm going to do. And I know I can't be the only one."
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Thousands piled into the comments—and not just to say "same." Some offered solidarity. Others dropped math. Many just tried to make peace with where they are.
"I just <a href="https://www.benzinga.com/personal-finance/25/02/43821356/take-a-450000-pension-in-a-lump-sum-or-3000-monthly-payments-suze-ormans-advice-to-anxious-soon-to-be-retiree">started saving for a pension</a> and I'm 33, literally because I finally managed to land a decent job," one user wrote. "That being said I can only afford to put $40 in a pay, which is abysmal."
Another chimed in: "Hey! Me too! Same age and everything!"
A few tried to keep the mood up: "$40 is $40 more than you were putting away."
"It adds up. Compound interest is real."
But not everyone was convinced that $40 and hope were enough.
"She's only got about 34 working years left which at the current rate she'll be able to invest $16,320," one commenter calculated. "At best you can expect to double your money every 10 years… That initial investment will be worth less than $50k in today's <a href="https://www.benzinga.com/money/smartasset">dollars by retirement age</a>."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Still, the thread had sparks of optimism. One person said their husband started contributing just six or seven years ago and has already accumulated $30,000 with employer matching. Another reached $20,000 in two years.
Even in the poverty finance subreddit, not everyone is giving up.
"Late 30s here. I got a decent job 8 years ago and it took me the majority of that to work out of debt. I'm saving as of the last few years, but I also had to move home. Rough time."
"This is happening to me now," another added. "I cried for like 5 days when I moved back home."
But here's the real question: Is it <a href="https://www.benzinga.com/personal-finance/24/08/40295808/youre-40-50-or-60-do-you-know-how-much-you-should-have-saved-for-retirement-by-now">too late to start saving</a> at 49? Not ideal, no—but hopeless? Definitely not.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;&nbsp;
Let's say that same 49-year-old starts contributing $500 a month right now. If they invest in a basic index fund with a 7% annual return, they'd have over $175,000 by age 65. Bump that to $1,000 a month and they're looking at more than $350,000—still shy of millionaire status, but enough to completely change their future.
The key? Starting now. Not perfect, not flashy—just consistent.
No, most <a href="https://www.benzinga.com/personal-finance/management/25/06/45825806/is-your-retirement-nest-egg-above-average-heres-what-people-have-in-their-401k-and-ira-at-each-age">people aren't maxing out 401(k)s</a> at 25. Many are just now landing stable jobs in their 30s and 40s. Some are contributing $40 a paycheck. Some are sitting on $900 and wondering what's next.
But they're all still in the game. And that's what matters.
Read Next:
<ul class="wp-block-list">
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

'I'm Almost 49 With Zero Retirement Savings And $900 In My Checking Account' — Internet Strangers Assure Her She Can Still Build A Nest Egg

Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) has outperformed the market over the past 20 years by 8.3% on an annualized basis producing an average annual return of 16.7%. Currently, Rollins has a market capitalization of $27.34 billion. 
Buying $1000 In ROL: If an investor had bought $1000 of ROL stock 20 years ago, it would be worth $22,616.86 today based on a price of $56.41 for ROL at the time of writing.
<h3>Rollins's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750199413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Rollins 20 Years Ago Would Be Worth This Much Today

Estée Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) stock has climbed steadily over the past three months and jumped more than 10% on Monday following the death of<a href="https://www.benzinga.com/news/entertainment/25/06/45943408/leonard-lauder-visionary-behind-estee-lauders-global-expansion-and-creator-of-clinique-aramis-dies-at-92"> Leonard Lauder,</a><a href="https://www.benzinga.com/news/entertainment/25/06/45943408/leonard-lauder-visionary-behind-estee-lauders-global-expansion-and-creator-of-clinique-aramis-dies-at-92"> a longtime executive and son of founder Estée Lauder.&nbsp;</a>
Estée Lauder is Michael Burry's only current long position. Here's what to know: 
The Details: According to its most recent SEC filing, Burry&#8217;s hedge fund Scion Asset Management <a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession">doubled its stake</a> in Estée Lauder in the first quarter of 2025.&nbsp;
Read Next:<a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare"> Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest</a>&nbsp;
During the first quarter, the investment firm purchased an additional 100,000 shares in the world's second-largest cosmetics company, bringing its total holdings to 200,000 shares.&nbsp;
Estée Lauder: Leonard Lauder, the influential executive who guided Estée Lauder from a single-brand operation to a global leader in the beauty industry, passed away last Saturday at the age of 92.
Shares of Estée Lauder stock jumped 10% in Monday's session following the death of Lauder. 
While it is unlikely that Burry foresaw a stock jump correlated to the death of a company executive, he did double his stake in the company and held it as his firm's only long position.&nbsp;
Burry&#8217;s move could reflect a strategic bet on a recession and the so-called "Lipstick Index," which suggests consumers turn to more affordable luxuries like cosmetics<a href="https://www.benzinga.com/markets/25/05/45484735/michael-burry-makes-major-portfolio-shift-holding-only-one-asset-he-deems-recession-proof"> during economic downturns.</a>
&#8220;In the 2008 recession, cosmetics sales increased, showing that even in tough times, individuals crave tiny comfort purchases that give psychological boosts without a hefty financial outlay,&#8221; Kevin Shahnazari, founder of FinlyWealth, told LevelFields.
EL Price Action: Estée Lauder shares ended Tuesday's session&nbsp;up 0.27% at $74.79, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next:<a href="https://www.benzinga.com/news/retail-sales/25/06/45953480/alibaba-pdd-stocks-climb-chinas-retail-sector-gains-despite-us-tariffs?utm_source=articleShare">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/retail-sales/25/06/45953480/alibaba-pdd-stocks-climb-chinas-retail-sector-gains-despite-us-tariffs?utm_source=articleShare">Alibaba, PDD Stocks Climb As China&#8217;s Retail Sector Gains Despite US Tariffs</a></li>
</ul>
Photo: Shutterstock

Hedge Funds

Management

Movers

Michael Burry Saw It Before Anyone Else — Then Estée Lauder's Story Took A Dramatic Turn

AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) has outperformed the market over the past 15 years by 4.17% on an annualized basis producing an average annual return of 16.17%. Currently, AMETEK has a market capitalization of $40.51 billion. 
Buying $1000 In AME: If an investor had bought $1000 of AME stock 15 years ago, it would be worth $9,449.46 today based on a price of $175.55 for AME at the time of writing.
<h3>AMETEK's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750198512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AMETEK 15 Years Ago Would Be Worth This Much Today

Several professional athletes have announced taking salary or endorsement money in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in recent years, <a href="https://www.benzinga.com/markets/cryptocurrency/21/07/21984141/nfls-saquon-barkley-to-take-100-of-endorsement-money-in-bitcoin">including NFL superstar</a> Saquon Barkley.
Here's a look back at his decision and how much investors could have made following the NFL star running back.
What Happened: Barkley, who won a Super Bowl with<a href="https://www.benzinga.com/general/sports-betting/24/03/37635003/super-bowl-betting-shakeup-how-top-nfl-signings-are-reshaping-the-odds"> the Philadelphia Eagles </a>last season, made a surprising announcement on July 14, 2021, when he announced he would take 100% of his endorsement money in Bitcoin.
The endorsement money was converted to Bitcoin via Strike, a Bitcoin payments company.
"You see inflation. You see how high it is right now," Barkley said at the time.
After missing time the previous season with an injury, Barkley discussed the dilemmas of having enough money in case his career was cut short.
"I'm gonna be taking my marketing money in Bitcoin," Barkley&nbsp;<a href="https://x.com/APompliano/status/1415354090645827590" target="_blank" rel="noreferrer noopener">announced&nbsp;</a>on "The Best Business Show With Anthony Pompliano."
When he entered the NFL, Barkley said his&nbsp;plan was to live off his marketing money and save his salary.
"This is the smart thing to do, the right thing to do."
Strike CEO Jack Mallers joined the show and said he was proud of Barkley for taking the step to preserve his wealth for himself and his family.
"His cash is going to be worth half as less in five years," Mallers said, citing inflation.
Mallers pointed out that the average NFL career is 3 1/2 years, providing financial uncertainties for athletes.
Barkley receives over $10 million in endorsements annually, <a href="https://twitter.com/JoePompliano/status/1415346064807366658" target="_blank" rel="noreferrer noopener">according </a>to Joe Pompliano, who was featured on the show.
Fast forward to 2025 and Barkley is proud of his decision and being able to silence the people who thought he was making a dumb decision.
"People are always gonna have something to say," Barkley <a href="https://x.com/coinbase/status/1933324509177577724">said </a>at the recent Coinbase State of Crypto Summit.
Barkley said the decision was made at the right time after talking with his manager, Mallers and Pompliano. Barkley also recalls that he had a phone call with Strategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) Executive Chairman Michael Saylor at the time.
"Back then, he told me I should take all my money and put it in, I think he's doing pretty well."
Barkley joked that maybe he should've listened to Saylor.
When it comes to finances and investment decisions, Barkley said he never wants to be the smartest person in the world.
"Surround yourself with super smart people."
Read Also: <a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a>
Investing $1,000 in Bitcoin: Today, Barkley is one of the most followed and talked about NFL stars, topping the league in 2024 for regular season rushes and rushing yards and setting career highs for the NFL star.
Investors who were fans of Barkley may have decided to invest in Bitcoin based on the comments made by the NFL star at the time.
A $1,000 investment in Bitcoin at the daily high on July 14, 2021, could have purchased 0.0302 BTC. Today, that $1,000 investment would be worth $3,155.50, up 215.6%.
Compare that to a $1,000 investment in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 and broader U.S. stock market. The same $1,000 invested in the SPY would be worth $1,362.37 today, up 36.2%.
Barkley's investment of his endorsement money in Bitcoin has significantly outperformed the S&amp;P 500.
What's Next: Barkley enters the 2025 NFL season with the Eagles, hoping to win a second straight Super Bowl.
The Eagles are the favorites to win Super Bowl LX with odds of +650 at the DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) sportsbook. Barkley is the favorite to win the Offensive Player of the Year award in the 2025 NFL season with odds of +650, which would be a second straight win for the Eagles RB.
Barkley will be hoping to escape the "Madden curse," which is often used to describe down years or injuries that happen to players who appear on the <a href="https://www.nfl.com/news/eagles-rb-saquon-barkley-s-reverse-hurdle-graces-cover-of-madden-nfl-26">cover </a>of the Madden video game.
The Eagles star is the cover athlete for the Madden NFL 26 cover from Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>). Barkley is on the cover doing his reverse hurdle move that he pulled off during a 2024 NFL season game and is also one of the few players to have a perfect 99 score in the game.
Barkley was recently named the number one player by sales for the 2024 season by the <a href="https://nflpa.com/partners/posts/things-to-know-about-the-2024-year-end-nflpa-top-50-player-sales-list#:~:text=Saquon%20Barkley%20claimed%20the%20retail,2017%20to%20finish%20No.%201.">NFLPA</a>, becoming the first running back to top the list since 2017. Barkley enters the 2025 season with high expectations and as one of the top players for fans.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45871245/exclusive-bitcoin-to-hit-200k-in-2025-15-say-yes-while-many-see-new-all-time-highs-coming">EXCLUSIVE: Bitcoin To Hit $200K In 2025? 15% Say Yes While Many See New All-Time Highs Coming</a></li>
</ul>
Photos: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Education

Sports

$BTC

DKNG

MSTR

If You Invested $1,000 In Bitcoin When NFL Star Saquon Barkley Took Endorsement Money In BTC, Here's How Much You'd Have Today

<a href="https://www.axios.com/2025/06/17/trump-situation-room-meeting-iran-israel-war">https://www.axios.com/2025/06/17/trump-situation-room-meeting-iran-israel-war</a>

General

iShares MSCI Israel Capped Investable Market Index Fund

'Trump speaks with Netanyahu after crucial meeting on Israel-Iran war'- Axios

<a href="https://www.axios.com/2025/06/17/senate-passes-genius-act-despite-crypto-corruption-concerns?utm_campaign=editorial&amp;utm_medium=social&amp;utm_source=twitter">https://www.axios.com/2025/06/17/senate-passes-genius-act-despite-crypto-corruption-concerns?utm_campaign=editorial&amp;utm_medium=social&amp;utm_source=twitter</a>

'Senate passes GENIUS Act despite crypto corruption concerns'- Axios

Looking into the current session, Cemex Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) shares are trading at $6.82, after a 1.16% drop. Over the past month, the stock decreased by 3.13%, but over the past year, it actually spiked by 6.57%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750197618_0.png" alt="Past Year Chart" />

<h3>How Does Cemex P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Cemex has a lower P/E than the aggregate P/E of 21.62 of the Construction Materials industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750197618_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Cemex Inc's Price Over Earnings

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 10 years by 3.41% on an annualized basis producing an average annual return of 14.32%. Currently, Morningstar has a market capitalization of $12.87 billion. 
Buying $1000 In MORN: If an investor had bought $1000 of MORN stock 10 years ago, it would be worth $3,790.20 today based on a price of $300.79 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750197616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<a href="https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-17-2025/card/trump-sparing-tiktok-from-ban-with-another-deadline-extension-ZQVod1UzdEvomPuyYyle?mod=Searchresults_pos1&amp;page=1">https://www.wsj.com/livecoverage/stock-market-today-trump-tariffs-trade-war-06-17-2025/card/trump-sparing-tiktok-from-ban-with-another-deadline-extension-ZQVod1UzdEvomPuyYyle?mod=Searchresults_pos1&amp;page=1</a>

AMZN

ORCL

PINS

SNAP

'Trump Sparing TikTok From Ban With Another Deadline Extension'- WSJ

FCPT

Four Corners Property Trust Acquires An Olive Garden Property For $4.1M

<a href="https://www.cnn.com/2025/06/17/politics/kristi-noem-hostpital">https://www.cnn.com/2025/06/17/politics/kristi-noem-hostpital</a>

'Homeland Security Secretary Kristi Noem transported by ambulance to DC-area hospital, sources say'- CNN

Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) has outperformed the market over the past 10 years by 5.53% on an annualized basis producing an average annual return of 16.45%. Currently, Booking Holdings has a market capitalization of $172.50 billion. 
Buying $100 In BKNG: If an investor had bought $100 of BKNG stock 10 years ago, it would be worth $460.80 today based on a price of $5301.05 for BKNG at the time of writing.
<h3>Booking Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750195824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BKNG

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares are trading lower in Tuesday&#8217;s after-hours session after the company announced a proposed private placement of <a href="https://www.benzinga.com/pressreleases/25/06/g45984139/bitdeer-announces-proposed-private-placement-of-us-300-0-million-of-convertible-senior-notes">convertible senior notes</a>.
What Happened: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining company Bitdeer announced plans to offer $300 million of convertible senior notes due 2031 in a private placement to institutional buyers. The company plans to grant the initial purchasers a 13-day window to purchase up to an additional $45 million of the notes.
Bitdeer expects to use a portion of the proceeds to pay the cost of a zero-strike call option transaction and to pay the cash consideration for concurrent note exchange transactions that involve privately negotiated agreements with one or more holders of 8.5% convertible senior notes due 2029.
The remaining proceeds will be used for data center expansions and ASIC-based mining rig development and manufacturing.
Bitdeer had $215.6 million in cash and cash equivalents as of March 31, as well as a total crypto balance of $131.1 million.
Last week, Bitdeer said it mined 196 Bitcoin in May, up 18.1% month-over-month. The company ended the month with a self-mining hashrate of 13.6 EH/s.
&#8220;Further, in May, we sold and shipped approximately 1.6 EH/s of our SEALMINER A2s to external customers. Our A3 Series will also be released and available for pre-order very soon,&#8221; the company said last week.
BTDR Price Action: <a href="http://benzinga.com/quote/BTDR">Bitdeer shares</a> were down 6.38% in after-hours Tuesday, trading at $12..70 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/45978954/kraken-partners-with-alpaca-to-expand-crypto-trading-to-financial-institutions">Kraken Partners With Alpaca To Expand Crypto Trading To Financial Institutions</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45957098/coinbase-to-benefit-from-political-landscape-analyst-says-now-is-buying-opportunity">Coinbase To Benefit From Political Landscape, Analyst Says Now Is &#8216;Buying Opportunity&#8217;</a></li>
</ul>
Photo: Yalcin Sonat/Shutterstock.

Offerings

After-Hours Center

BTDR

Bitcoin Mining Stock Bitdeer Technologies Is Sliding After The Bell: What's Sparking The Sell-Off?

BREA

Brera Holdings Entered Into Subscription Agreement, To Sell 2.1M Class B Ordinary Shares

Earnings

BANX

CORRECTION: ArrowMark Financial Q1 EPS $0.58 Down From $0.70 YoY

<a href="https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa" title="https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/business/retail/hasbro-trims-3-of-workforce-in-cost-cutting-push-2ac88b24?msockid=21c662101c496b42343370ae1de86aaa</a>

Hasbro Spokeswoman Says Hasbro Is Aligning Cost Structure With Long-Term Goals; Hasbro Job Cuts Amount to Roughly 150 Workers; Hasbro Cuts 3% of Workforce

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 10 years by 3.61% on an annualized basis producing an average annual return of 14.53%. Currently, CoStar Group has a market capitalization of $33.69 billion. 
Buying $100 In CSGP: If an investor had bought $100 of CSGP stock 10 years ago, it would be worth $383.50 today based on a price of $79.89 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750194912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

Here's How Much You Would Have Made Owning CoStar Group Stock In The Last 10 Years

WIIM

MMA stock has given up its prior loss. Mixed Martial Arts Group shares were trading lower after the company announced the pricing of a $5 million underwritten public offering at $0.76 per share.

Transactions to generate $14 million of liquidity and reduce non-floorplan indebtedness by $15 million
Continues to focus on strengthening the balance sheet in support of long-term stability, improving operational performance of dealerships, and strategically divesting non-core assets
TAMPA, Fla., June 17, 2025 /PRNewswire/ -- Lazydays Holdings, Inc.&nbsp;("Lazydays" or the "Company") (NasdaqCM: GORV) today announced that it has executed amendments and waivers with its credit facility lender syndicate led by M&amp;T Bank and its mortgage lender, an affiliate of Coliseum Capital Management, that will help to enhance the Company's liquidity position and further fortify its financial foundation.
Under the terms of the transactions, Lazydays will retain approximately $14 million of proceeds resulting from its divestures of certain non-core dealerships and associated real estate, and repay approximately $15 million in non-floorplan indebtedness, reducing non-floorplan indebtedness to approximately $44 million and meaningfully lowering interest expense.
The contributing divestitures are as follows:
<ul>
<li>Divestiture of dealership in Mesa, AZ, which closed on May 30, 2025;</li>
<li>Divestiture of dealership and related real estate in Fort Pierce, FL, which closed on June 6, 2025;</li>
<li>Divestiture of dealership in&nbsp;Longmont, CO, which closed on June 13, 2025; and</li>
<li>Divestiture of dealership and related real estate in Las Vegas, NV, which is expected to close later this week.</li>
</ul>

GORV

Lazydays Executes Credit Amendments And Non-Core Dealership Divestitures To Generate $14M Liquidity, Reduce Non-Floorplan Debt By $15M

Press Releases

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

Legal

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European  Patent Application Allowance Regarding Company's Lead Compound CER-1236

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside

BGSF

CERO

INEO

PCSA

PNPNF

PRPH

PRSO

SAFX

SNYR

TSXV:PNPN

XTIA

Aditxt

Alzamend Neuro

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Oragenics

Onconetix

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Maxim Group

CERo Therapeutics shares are trading higher after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.

Comments

CERo Therapeutics Hldgs

Intérêt court

CERo Therapeutics Hldgs (NASDAQ:CERO) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL